Browse EX-10 agreements

**ATTOVIA THERAPEUTICS, INC. **

**NON-EMPLOYEE DIRECTOR COMPENSATION POLICY **

Each member of the Board of Directors (the “Board”) of Attovia Therapeutics, Inc. (the “Company”) who is a non-employee director of the Company (each, a “Non-Employee Director”) will receive the compensation described in this Non-Employee Director Compensation Policy (this “Policy”) for such Non-Employee Director’s service on the Board. This Policy is effective as of the closing of the sale of shares of the Company’s common stock (the “Common Stock”) to the public pursuant to a registration statement declared effective by the U.S. Securities and Exchange Commission (the “IPO” and such date, the “Effective Date”). This Policy may be amended or terminated at any time in the sole discretion of the Board.

1.	**Cash Compensation **

…

**ATTOVIA THERAPEUTICS, INC. **

July 20, 2026

Hubert Chen

*Sent via email *

RE: Continued Employment with Attovia Therapeutics, Inc.

Dear Hubert:

This letter agreement (“Agreement”) amends and restates the offer letter between you and Attovia Therapeutics, Inc. (the “Company”), dated on or about January 22, 2024 (the “Prior Agreement”) and sets forth the terms of your continued employment with the Company or a subsidiary of the Company. This Agreement is effective as of the closing of the sale of shares of the Company’s common stock to the public pursuant to a registration statement declared effective by the U.S. Securities and Exchange Commission. The terms of your continued employment and the benefits currently provided by the Company are as set forth in this Agreement.

You will continue to work in the role of Chief Medical Officer, an exempt position, reporting to the Company’s Chief Executive Officer.

…

**ATTOVIA THERAPEUTICS, INC. **

July 20, 2026

Tao Fu

*Sent via email *

RE: Continued Employment with Attovia Therapeutics, Inc.

Dear Tao:

This letter agreement (“Agreement”) amends and restates the offer letter between you and Attovia Therapeutics, Inc. (the “Company”), dated on or about June 2, 2023 (the “Prior Agreement”) and sets forth the terms of your continued employment with the Company or a subsidiary of the Company. This Agreement is effective as of the closing of the sale of shares of the Company’s common stock to the public pursuant to a registration statement declared effective by the U.S. Securities and Exchange Commission. The terms of your continued employment and the benefits currently provided by the Company are as set forth in this Agreement.

You will continue to work in the role of Chief Executive Officer, an exempt position, reporting to the Company’s Board of Directors.

…

**ATTOVIA THERAPEUTICS, INC. **

July 20, 2026

Petter Veiby

*Sent via email *

RE: Continued Employment with Attovia Therapeutics, Inc.

Dear Petter:

This letter agreement (“Agreement”) amends and restates the offer letter between you and Attovia Therapeutics, Inc. (the “Company”), dated on or about June 19, 2023 (the “Prior Agreement”) and sets forth the terms of your continued employment with the Company or a subsidiary of the Company. This Agreement is effective as of the closing of the sale of shares of the Company’s common stock to the public pursuant to a registration statement declared effective by the U.S. Securities and Exchange Commission. The terms of your continued employment and the benefits currently provided by the Company are as set forth in this Agreement.

You will continue to work in the role of Chief Scientific Officer, an exempt position, reporting to the Company’s Chief Executive Officer.

…

**ATTOVIA THERAPEUTICS, INC. **

**2026 EMPLOYEE STOCK PURCHASE PLAN **

1. PURPOSE. The purpose of this Plan is to provide eligible employees of Attovia Therapeutics, Inc. (the “Company”) and the Participating Corporations with a means of acquiring an equity interest in the Company, to enhance such employees’ sense of participation in the affairs of the Company. Capitalized terms not defined elsewhere in the text are defined in Section*** 28* of this Plan.

…

**ATTOVIA THERAPEUTICS, INC. **

**EXECUTIVE CHANGE IN CONTROL AND SEVERANCE PLAN **

This Executive Change in Control and Severance Plan (this “Plan”) of Attovia Therapeutics, Inc., a Delaware corporation (the “Company”) was adopted by the Company’s Board of Directors (the “Board”), to become effective as of the first date on which the Registration Statement on Form S-1 for the initial public offering of the Company’s common stock is declared effective by the United States Securities and Exchange Commission (the “Effective Date”). This Plan sets forth the terms and conditions under which the Company will provide certain severance payments and benefits to Participants (as defined below) upon separation of employment from the Company.

1. Eligibility.

…

**ATTOVIA THERAPEUTICS, INC. **

**2026 EQUITY INCENTIVE PLAN **

1. PURPOSE. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to the success of the Company, and any Parents, Subsidiaries and Affiliates that exist now or in the future, by offering them an opportunity to participate in the Company’s future performance through the grant of Awards. Capitalized terms not defined elsewhere in the text are defined in Section*** 2*8 of this Plan.

2. SHARES SUBJECT TO THIS PLAN.

…

STANDSTILL AGREEMENT

This Standstill Agreement (this “Agreement”) is entered into as of July 28, 2026 (the “Effective Date”) by and between Streeterville Capital, LLC, a Utah limited liability company (“Investor”), and Professional Diversity Network, a Delaware corporation (“Company”). Capitalized terms used in this Agreement without definition shall have the meanings given to them in PPP #1 (defined below).

A.    Company previously sold and issued to Investor that certain Pre-Paid Purchase #1 dated September 5, 2025, as amended, in the original principal amount of $8,655,000.00 (the “PPP #1”) pursuant to that certain Securities Purchase Agreement dated September 5, 2025 by and between Investor and Company (the “Purchase Agreement”, and together with all other documents entered into in conjunction therewith, the “Transaction Documents”).

B.    Company has requested and Investor has agreed, subject to the terms, conditions and understandings expressed in this Agreement, to refrain and forbear temporarily from making purchases under PPP #1.

…

SECURITIES PURCHASE AGREEMENT

THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of [ ], 2026, between Professional Diversity Network, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act (as defined below), the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

ARTICLE I.
DEFINITIONS

…

Form of Lock-Up Agreement

[ ], 2026

Maxim Group LLC

300 Park Avenue, 16th Floor

New York, NY 10022

Ladies and Gentlemen:

The undersigned understands that Maxim Group LLC (the “Placement Agent”) proposes to enter into a Placement Agency Agreement (the “Agreement “) with Professional Diversity Network, Inc., a Delaware corporation (the “Company”), providing for the public offering (the “Public Offering”) of certain securities of the Company.

…

PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT

THIS PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT, dated as of [_________], 2026 (as it may from time to time be amended, this “Agreement”), is entered into by and between Dune Acquisition Corporation III, a Cayman Islands exempted company (the “Company”), and Clear Street LLC, a Delaware limited liability company (the “Purchaser”).

** **

WHEREAS, the Company intends to consummate an initial public offering of the Company’s units (the “Public Offering”), each unit consisting of one Class A Ordinary Share, par value $0.0001 per share, of the Company (an “Ordinary Share”), and one-half of one redeemable warrant. Each whole warrant entitles the holder to purchase one Ordinary Share at an exercise price of $11.50 per Ordinary Share. The Purchaser has agreed to purchase an aggregate of 250,000 warrants (whether or not the underwriter’s over-allotment option is exercised) (the “Private Placement Warrants”), each Private Placement Warrant entitling the holder to purchase one Ordinary Share at an exer

…

** **

February 23, 2026

Dune Acquisition Corporation III
700 S. Rosemary Avenue, Suite 204
West Palm Beach, FL 33401

	Re:	Initial Public Offering

Ladies and Gentlemen:

This letter (this “Letter Agreement”) is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”) entered into by and between Dune Acquisition Corporation III, a Cayman Islands exempted company (the “Company”), and Clear Street LLC, as representative (the “Representative”) of the underwriters (the “Underwriters”), relating to an underwritten initial public offering (the “Public Offering”) of up to 11,500,000 of the Company’s units (including up to 1,500,000 units which may be purchased to cover over-allotments, if any) (the “Units”), each comprised of one Class A ordinary share, par value $0.0001 per share, of the Company (the “Class A Ordinary Shares”) and one-half of one redeemable warrant (each whole warrant, a “Warrant”). Each Warrant entitl

…